biote Corp. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 48/100
What the filing says
Biote reported Q2 2026 revenue of $44.2M (down 9.5% YoY from $48.9M) and net loss of $7.4M (vs. net income of $3.9M in Q2 2025). Procedure revenue fell 13.9% to $30.3M due to a January 2026 voluntary recall of hormone pellets by Asteria Health; gross margin compressed 620 bps to 65.4% from higher third-party sourcing costs and reduced manufacturing efficiency. Adjusted EBITDA declined 63% to $5.6M. The company revised full-year 2026 guidance to above $175M revenue and above $25M Adjusted EBITDA, acknowledging delayed return to YoY procedure revenue growth. Cash decreased to $11.2M from $24.1M at year-end 2025; term loan increased to $118.4M.
Why this rating
Product recall caused material ~10% revenue drop and 63% Adj. EBITDA decline. At $97.9M market cap, $4.7M incremental loss in six months is ~5% of market value. Recall is temporary headwind, but near-term cash burn (down $13M in 6 months) and rising debt offset recovery narrative. Moderate relative impact.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.